The effect of bevacizumab treatment on reading ability in age related macular degeneration - Reading after bevacizumab treatment in AMD

Phase 1

• Conditions: Age related macular degeneration of the eye, wet form; MedDRA version: 12.1 Level: LLT Classification code 10064930 Term: Age-related macular degeneration

• Registration Number: EUCTR2010-024001-12-FI
• Lead Sponsor: TYKS

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-12-02
• Last Update Posted: 10 December 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

Patients from the Department of Ophthalmology, Turku University Hospital, which have wet form of age related macular degeneration of the eye and are decided to be treated with intravitreal bevacizumab according to hospitals routine clinical guidelines.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

No other eye diseases

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: to document the effect of intravitreal bevacizumab treatment on reading ability and foveal and parafoveal vision in age related macular degeneration (wet form);Secondary Objective: to validate internationally comparable methods for measuring reading ability;Primary end point(s): Follow up visit 12 months after first intravitreal bevacizumab injection.